Boehringer Ingelheim initiates Phase II study of BI 1815368, a potential first-in-class oral treatment for diabetic macular edema
Notified -
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-07-07, 18:00
Email: info@10toptenreviews.com
10 Top Ten Reviews is part of VSG Solution JSC, an international media group and leading digital publisher.
© 2021 - 10TopTenReiews All Rights Reserved.